A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)

PHASE3TerminatedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

September 15, 2021

Primary Completion Date

May 25, 2023

Study Completion Date

May 25, 2023

Conditions
Takayasu Arteritis
Interventions
DRUG

Ustekinumab

Participants will receive IV infusion and SC injection of ustekinumab.

OTHER

Placebo

Participants will receive IV infusion and SC injection of matching placebo.

DRUG

Glucorticoid Taper Regimen

Glucocorticoid will be administered orally.

Trial Locations (27)

113 8519

Tokyo Medical and Dental University Hospital, Bunkyō City

260 8677

Chiba University Hospital, Chiba

812 8582

Kyushu University Hospital, Fukuoka

431 3192

Hamamatsu University Hospital, Hamamatsu

350-0495

Saitama Medical University Hospital, Iruma-gun

761 0793

Kagawa University Hospital, Kita Gun

650 0017

Kobe University Hospital, Kobe

606-8507

Kyoto University Hospital, Kyoto

790-8524

Matsuyama Red Cross Hospital, Matsuyama

467 8602

Nagoya City University Hospital, Nagoya

951 8520

Niigata University Medical And Dental Hospital, Niigata

700 8558

Okayama University Hospital, Okayama

530-8480

Kitano Hospital, Osaka

598-8577

Rinku General Medical Center, Osaka

589 8511

Kindai University Hospital, Osaka Sayama Shi

252-0375

Kitasato University Hospital, Sagamihara

060-8543

Sapporo Medical University Hospital, Sapporo

060-8648

Hokkaido University Hospital, Sapporo

980 8574

Tohoku University Hospital, Sendai

162 8655

Center Hospital of the National Center for Global Health and Medicine, Shinjuku Ku

564-8565

National Cerebral and Cardiovascular Center, Suita-Shi

101-8643

Mitsui Memorial Hospital, Tokyo

104 8560

St. Luke's International Hospital, Tokyo

470-1192

Fujita Health University Hospital, Toyoake

305 8576

University of Tsukuba Hospital, Tsukuba

641 8510

Wakayama Medical University Hospital, Wakayama

683-8504

Tottori University Hospital, Yonago

Sponsors
All Listed Sponsors
lead

Janssen Pharmaceutical K.K.

INDUSTRY